Exelixis Inc. (NASDAQ:EXEL) went up by 3.56% from its latest closing price compared to the recent 1-year high of $27.35. The company’s stock price has collected -4.69% of loss in the last five trading sessions. Press Release reported on 07/08/21 that Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021
Is It Worth Investing in Exelixis Inc. (NASDAQ :EXEL) Right Now?
Exelixis Inc. (NASDAQ:EXEL) scored a price-to-earnings ratio above its average ratio, recording 84.40 x from its present earnings ratio. Plus, the 36-month beta value for EXEL is at 1.03. Opinions of the stock are interesting as 11 analysts out of 14 who provided ratings for Exelixis Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $29.54. EXEL currently public float of 306.58M and currently shorts hold a 3.96% ratio of that float. Today, the average trading volume of EXEL was 2.19M shares.
EXEL’s Market Performance
EXEL stocks went down by -4.69% for the week, with a monthly drop of -24.68% and a quarterly performance of -31.13%, while its annual performance rate touched -34.06%. The volatility ratio for the week stands at 3.32% while the volatility levels for the past 30 days are set at 3.86% for Exelixis Inc.. The simple moving average for the period of the last 20 days is -11.41% for EXEL stocks with a simple moving average of -23.26% for the last 200 days.
Analysts’ Opinion of EXEL
Many brokerage firms have already submitted their reports for EXEL stocks, with H.C. Wainwright repeating the rating for EXEL by listing it as a “Buy.” The predicted price for EXEL in the upcoming period, according to H.C. Wainwright is $47 based on the research report published on June 15th of the current year 2021.
Goldman, on the other hand, stated in their research note that they expect to see EXEL reach a price target of $23. The rating they have provided for EXEL stocks is “Sell” according to the report published on May 18th, 2021.
Credit Suisse gave a rating of “Outperform” to EXEL, setting the target price at $30 in the report published on March 31st of the current year.
EXEL Trading at -22.04% from the 50-Day Moving Average
After a stumble in the market that brought EXEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.28% of loss for the given period.
Volatility was left at 3.86%, however, over the last 30 days, the volatility rate increased by 3.32%, as shares sank -25.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.78% lower at present.
During the last 5 trading sessions, EXEL fell by -4.69%, which changed the moving average for the period of 200-days by -31.21% in comparison to the 20-day moving average, which settled at $18.76. In addition, Exelixis Inc. saw -15.89% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at EXEL starting from Lamb Peter, who sale 60,000 shares at the price of $17.47 back on Jul 15. After this action, Lamb Peter now owns 389,467 shares of Exelixis Inc., valued at $1,048,200 using the latest closing price.
Lamb Peter, the EVP, Scientific Strategy & CSO of Exelixis Inc., sale 60,000 shares at $22.18 during a trade that took place back on Jun 17, which means that Lamb Peter is holding 389,467 shares at $1,330,800 based on the most recent closing price.
Stock Fundamentals for EXEL
Current profitability levels for the company are sitting at:
- +11.14 for the present operating margin
- +96.33 for the gross margin
The net margin for Exelixis Inc. stands at +11.32. The total capital return value is set at 6.00, while invested capital returns managed to touch 6.10. Equity return is now at value 3.50, with 3.10 for asset returns.
Based on Exelixis Inc. (EXEL), the company’s capital structure generated 2.77 points at debt to equity in total, while total debt to capital is 2.70. Total debt to assets is 2.43, with long-term debt to equity ratio resting at 2.61. Finally, the long-term debt to capital ratio is 2.54.
When we switch over and look at the enterprise to sales, we see a ratio of 5.29, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 6.92 and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.06.